```
Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:SSPTAJDA1614

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1          Web Page for STN Seminar Schedule - N. America
 NEWS  2  NOV 21  CAS patent coverage to include exemplified prophetic
                  substances identified in English-, French-, German-,
                  and Japanese-language basic patents from 2004-present
 NEWS  3  NOV 26  MARPAT enhanced with FSORT command
 NEWS  4  NOV 26  CHEMSAFE now available on STN Easy
 NEWS  5  NOV 26  Two new SET commands increase convenience of STN
                  searching
 NEWS  6  DEC 01  ChemPort single article sales feature unavailable
 NEWS  7  DEC 12  GBFULL now offers single source for full-text
                  coverage of complete UK patent families
 NEWS  8  DEC 17  Fifty-one pharmaceutical ingredients added to PS
 NEWS  9  JAN 06  The retention policy for unread STNmail messages
                  will change in 2009 for STN-Columbus and STN-Tokyo
 NEWS 10  JAN 07  WPIDS, WPINDEX, and WPIX enhanced Japanese Patent
                  Classification Data
 NEWS 11  FEB 02  Simultaneous left and right truncation (SLART) added
                  for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
 NEWS 12  FEB 02  GENBANK enhanced with SET PLURALS and SET SPELLING
 NEWS 13  FEB 06  Patent sequence location (PSL) data added to USGENE
 NEWS 14  FEB 10  COMPENDEX reloaded and enhanced
 NEWS 15  FEB 11  WTEXTILES reloaded and enhanced

 NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 09:43:42 ON 18 FEB 2009

=> file registry
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
```

FULL ESTIMATED COST 0.22 0.22

FILE 'REGISTRY' ENTERED AT 09:44:00 ON 18 FEB 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 17 FEB 2009 HIGHEST RN 1107694-62-1
DICTIONARY FILE UPDATES: 17 FEB 2009 HIGHEST RN 1107694-62-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

```
=> E "TENATOPRAZOLE"/CN 25
E1            1     TENATE/CN
E2            1     TENATHAN/CN
E3            1 --> TENATOPRAZOLE/CN
E4            1     TENATOPRAZOLE CALCIUM/CN
E5            1     TENATOPRAZOLE LITHIUM/CN
E6            1     TENATOPRAZOLE MAGNESIUM/CN
E7            1     TENATOPRAZOLE POTASSIUM/CN
E8            1     TENATOPRAZOLE SODIUM/CN
E9            1     TENATOPRAZOLE SULFIDE/CN
E10           2     TENAX/CN
E11           1     TENAX (POLYESTER)/CN
E12           1     TENAX (POLYETHER)/CN
E13           1     TENAX 2010/CN
E14           1     TENAX 300/CN
E15           1     TENAX 316L/CN
E16           1     TENAX 424/CN
E17           1     TENAX 428/CN
E18           1     TENAX 452/CN
E19           1     TENAX 5001/CN
E20           1     TENAX 5N21/CN
E21           1     TENAX F 201/CN
E22           1     TENAX GC/CN
E23           1     TENAX GC 80/100/CN
E24           1     TENAX GR/CN
E25           1     TENAX H/CN

=> S E3
L1            1 TENATOPRAZOLE/CN

=> DIS L1 1 SQIDE

L1   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2009 ACS on STN
RN   113712-98-4  REGISTRY
CN   3H-Imidazo[4,5-b]pyridine, 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-
```

pyridinyl)methyl]sulfinyl]- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1H-Imidazo[4,5-b]pyridine, 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]- (9CI)
OTHER NAMES:
CN (±)-Tenatoprazole
CN 5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-imidazo[4,5-b]pyridine
CN 5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl]-1H-imidazo[4,5-b]pyridine
CN Tenatoprazole
CN TU 199
MF C16 H18 N4 O3 S
CI COM
SR CA
LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BIOSIS, CA, CAPLUS, CASREACT, CHEMCATS, CSCHEM, EMBASE, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, PHAR, PROMT, PROUSDDR, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
DT.CA CAplus document type: Journal; Patent
RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); PRPH (Prophetic); RACT (Reactant or reagent); USES (Uses)
RLD.P Roles for non-specific derivatives from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)
RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

150 REFERENCES IN FILE CA (1907 TO DATE)
13 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
151 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s e3 or e4 or e5 or e6 or e7 or e8
1 TENATOPRAZOLE/CN
1 "TENATOPRAZOLE CALCIUM"/CN
1 "TENATOPRAZOLE LITHIUM"/CN
1 "TENATOPRAZOLE MAGNESIUM"/CN
1 "TENATOPRAZOLE POTASSIUM"/CN
1 "TENATOPRAZOLE SODIUM"/CN
L2 6 TENATOPRAZOLE/CN OR "TENATOPRAZOLE CALCIUM"/CN OR "TENATOPRAZOLE LITHIUM"/CN OR "TENATOPRAZOLE MAGNESIUM"/CN OR "TENATOPRAZOLE POTASSIUM"/CN OR "TENATOPRAZOLE SODIUM"/CN

=> E "CELECOXIB"/CN 25
E1 1 CELEC K/CN
E2 1 CELECOX/CN
E3 1 --> CELECOXIB/CN

```
E4            1     CELECOXIB CALCIUM/CN
E5            1     CELECOXIB LITHIUM/CN
E6            1     CELECOXIB POTASSIUM/CN
E7            1     CELECOXIB SODIUM/CN
E8            1     CELECOXIB SODIUM HYDRATE/CN
E9            1     CELECT AMINE/CN
E10           1     CELECT H 150/CN
E11           1     CELECT H 75/CN
E12           1     CELECT P 175/CN
E13           1     CELECT-P 1/CN
E14           1     CELECTOL/CN
E15           1     CELEKA/CN
E16           1     CELELLOSE/CN
E17           1     CELEMIC/CN
E18           1     CELENAMIDE A/CN
E19           1     CELENAMIDE B/CN
E20           1     CELENAMIDE C/CN
E21           1     CELENAMIDE D/CN
E22           1     CELENAMIDE E/CN
E23           1     CELENAR/CN
E24           1     CELENE DFD 6001/CN
E25           1     CELENE DFD 6005/CN

=> S E3
L3            1 CELECOXIB/CN

=> DIS L3 1 SQIDE

L3   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2009 ACS on STN
RN   169590-42-5  REGISTRY
CN   Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-
     yl]-  (CA INDEX NAME)
OTHER NAMES:
CN   4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-
     yl]benzenesulfonamide
CN   Celebra
CN   Celebrex
CN   Celecox
CN   Celecoxib
CN   Celocoxib
CN   SC 58635
CN   YM 177
DR   184007-95-2, 194044-54-7
MF   C17 H14 F3 N3 O2 S
CI   COM
SR   US Adopted Names Council (USAN)
LC   STN Files:   ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BIOSIS, BIOTECHNO,
       CA, CABA, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHEM, DDFU,
       DRUGU, EMBASE, HSDB*, IMSCOSEARCH, IMSDRUGNEWS, IMSPATENTS, IMSPRODUCT,
       IMSRESEARCH, IPA, MEDLINE, MRCK*, MSDS-OHS, PATDPASPC, PHAR, PROMT,
       PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
         (*File contains numerically searchable property data)
DT.CA  CAplus document type:  Book; Conference; Dissertation; Journal; Patent
RL.P   Roles from patents:  ANST (Analytical study); BIOL (Biological study);
       PREP (Preparation); PROC (Process); PRP (Properties); PRPH (Prophetic);
       RACT (Reactant or reagent); USES (Uses)
RLD.P  Roles for non-specific derivatives from patents:  ANST (Analytical
       study); BIOL (Biological study); PREP (Preparation); PROC (Process); PRP
       (Properties); USES (Uses)
RL.NP  Roles from non-patents:  ANST (Analytical study); BIOL (Biological
       study); FORM (Formation, nonpreparative); MSC (Miscellaneous); OCCU
       (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT
```

(Reactant or reagent); USES (Uses)
RLD.NP Roles for non-specific derivatives from non-patents: BIOL (Biological study); FORM (Formation, nonpreparative); PREP (Preparation); PROC (Process); PRP (Properties); USES (Uses)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3310 REFERENCES IN FILE CA (1907 TO DATE)
78 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
3330 REFERENCES IN FILE CAPLUS (1907 TO DATE)

```
=> s e3 or e4 or e5 or e6 or e7 or e8
             1 CELECOXIB/CN
             1 "CELECOXIB CALCIUM"/CN
             1 "CELECOXIB LITHIUM"/CN
             1 "CELECOXIB POTASSIUM"/CN
             1 "CELECOXIB SODIUM"/CN
             1 "CELECOXIB SODIUM HYDRATE"/CN
L4           6 CELECOXIB/CN OR "CELECOXIB CALCIUM"/CN OR "CELECOXIB LITHIUM"/CN
               OR "CELECOXIB POTASSIUM"/CN OR "CELECOXIB SODIUM"/CN OR "CELECO
               XIB SODIUM HYDRATE"/CN

=> file medline caplus wpids uspatfull
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                               80.92      81.14

FILE 'MEDLINE' ENTERED AT 09:46:28 ON 18 FEB 2009

FILE 'CAPLUS' ENTERED AT 09:46:28 ON 18 FEB 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 09:46:28 ON 18 FEB 2009
COPYRIGHT (C) 2009 THOMSON REUTERS

FILE 'USPATFULL' ENTERED AT 09:46:28 ON 18 FEB 2009
CA INDEXING COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

=> s l2 and l4
L5           10 L2 AND L4

=> d l5 1-10 ibib, abs, hitstr
```

L5 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:1282007 CAPLUS
DOCUMENT NUMBER: 149:478750
TITLE: Niacin-based pharmaceutical compositions
INVENTOR(S): Hight, H. Thomas
PATENT ASSIGNEE(S): USA
SOURCE: PCT Int. Appl., 31pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008127893	A1	20081023	WO 2008-US59425	20080404

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:

US 2007-921727P	P	20070404
US 2008-11302P	P	20080116
US 2008-63484P	P	20080204
US 2008-72489P	P	20080331

AB The disclosure relates generally to niacin-based pharmaceutical compns. that include at least one pharmaceutical agent capable of treating a niacin-induced side effect, such as flushing, hyperglyceremia, pruritis, a gastrointestinal side effect and hyperuricemia. Accordingly, one aspect of this disclosure is a pharmaceutical composition for delivering niacin to a patient in need thereof, wherein the composition comprises a therapeutic dose of niacin and a therapeutically ED of at least one pharmaceutical agent capable of reducing an adverse side-effect of niacin in the patient, and wherein the pharmaceutical agent is delivered to the patient jointly with the niacin, preferably as a single dosage pill or tablet. Thus, 13 patients, who initiated sustained-release niacin therapy using 81 mg of aspirin for prevention of flushing, continued to have debilitating flushing. They were then treated with a more potent NSAID, together with a proton pump inhibitor (PPI) to prevent gastrointestinal (GI) complications. Instead of aborting their niacin therapy, 12 patients were able to continue. The flushing was abolished or was made tolerable, with no NSAID-related GI complications.

IT 113712-98-4, Tenatoprazole 169590-42-5, Celecoxib
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. for niacin therapy comprising agents capable of reducing niacin-induced side effects)

RN 113712-98-4 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine, 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]- (CA INDEX NAME)



RN 169590-42-5 CAPLUS
CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:1278424 CAPLUS
DOCUMENT NUMBER: 149:471483
TITLE: Preparation of deuterium enriched tenatoprazole derivatives as proton pump modulators
INVENTOR(S): Gant, Thomas G.; Sarshar, Sepehr
PATENT ASSIGNEE(S): Auspex Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 107pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008127640	A2	20081023	WO 2008-US4689	20080411
WO 2008127640	A3	20081204		

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,

AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
PRIORITY APPLN. INFO.: US 2007-911264P P 20070411
OTHER SOURCE(S): MARPAT 149:471483
GI



I



II

AB The title compds. with general formula I [wherein R1 = -C(R11)(R12)(R13); R2 = -C(R14)(R15)(R16); R3 = -C(R17)(R18)(R19); R4 = -C(R20)(R21)(R22); R5 - R22 = independently hydrogen or deuterium, with the proviso that at least one of R5 - R22 is deuterium, and when R17, R18, and R19 are each deuterium, then at least one of R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R20, R21, and R22 is deuterium] or pharmaceutically acceptable salts, solvates, or prodrugs thereof were prepared as proton pump modulators. For example, 2-mercapto-5-(methoxy-d3)-3H-imidazolo[4,5-b]pyridine (preparation given) was reacted with methanesulfonic acid d9-3,5-dimethyl-4-nitro-pyridin-2-ylmethyl ester (preparation given) for d12-2-[[(3,5-dimethyl-4-nitro-2-pyridinyl)methyl]thio]-5-methoxy-1H-imidazo[4,5-b]pyridine, which was then reacted with d3-sodium methoxide in d4-methanol, oxidized with MCPBA, and finally treated with deuterium oxide to give II as a final product. The invention compds. were evaluated for their proton pump modulatory activity.

IT 113712-98-4, Tenatoprazole 169590-42-5, Celecoxib
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(codrug; preparation of deuterium enriched tenatoprazole derivs. as proton pump modulators)

RN 113712-98-4 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine, 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]- (CA INDEX NAME)



RN 169590-42-5 CAPLUS
CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)



L5 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:1251528 CAPLUS
DOCUMENT NUMBER: 149:471481
TITLE: Substituted benzimidazoles as proton pump modulators and their preparation and use in the treatment of diseases
INVENTOR(S): Gant, Thomas G.; Sarshar, Sepehr
PATENT ASSIGNEE(S): Auspex Pharmaceuticals, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 69pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20080255200	A1	20081016	US 2008-100992	20080410
WO 2008130863	A2	20081030	WO 2008-US59938	20080410

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2007-911266P P 20070411
OTHER SOURCE(S): MARPAT 149:471481
GI



I



II

AB Disclosed herein are substituted benzimidazole-based proton pump modulators of formula I, processes of preparation thereof, pharmaceutical compns. thereof, and methods of use thereof. Compds. of formula I wherein R1 is CR14R16R17; R2 is CR18R19R20; R2 - R20 are independently H and D; provided that at least one of R3 - R20 is D; and pharmaceutically acceptable salts, solvates and prodrugs thereof, are claimed. Example compound II was prepared by a multistep procedure. The invention compds. were evaluated for their proton pump modulatory activity (some data given).

IT 113712-98-4, Tenatoprazole 169590-42-5, Celecoxib
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(codrug; preparation of substituted benzimidazole-based proton pump modulators useful in treatment and prevention of proton pump-mediated disorders)

RN 113712-98-4 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine, 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]- (CA INDEX NAME)



RN 169590-42-5 CAPLUS
CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)



L5 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:888510 CAPLUS
DOCUMENT NUMBER: 149:192025
TITLE: Xanthine oxidoreductase inhibitors plus antiinflammatory agents for prevention of gout flares
INVENTOR(S): Lademacher, Christopher; Mcdonald, Patricia; Ridge, Nancy J.; Taneja, Rajneesh
PATENT ASSIGNEE(S): Tap Pharmaceutical Products, USA
SOURCE: PCT Int. Appl., 43pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008089296	A1	20080724	WO 2008-US51248	20080117
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 20090042887	A1	20090212	US 2008-15527	20080117
PRIORITY APPLN. INFO.:			US 2007-881794P P	20070119

OTHER SOURCE(S): MARPAT 149:192025

AB The invention relates to methods of preventing gout flares in a subject in need thereof by administering to the subject a therapeutically effective amount of at least one xanthine oxidoreductase inhibiting compound or salt thereof and at least one non-steroidal anti-inflammatory drug for a period of six months on a regular basis.

IT 113712-98-4, Tenatoprazole 113712-98-4D, Tenatoprazole, salts, amides, or derivs. 169590-42-5, Celecoxib 169590-42-5D, Celecoxib, salts
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(xanthine oxidoreductase inhibitors plus antiinflammatory agents for

prevention of gout flares)

RN 113712-98-4 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine, 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]- (CA INDEX NAME)



RN 113712-98-4 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine, 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]- (CA INDEX NAME)



RN 169590-42-5 CAPLUS

CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)



RN 169590-42-5 CAPLUS

CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:902714 CAPLUS
DOCUMENT NUMBER: 143:235463
TITLE: Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent
INVENTOR(S): Proehl, Gerald T.; Olmstead, Kay; Hall, Warren
PATENT ASSIGNEE(S): Santarus, Inc., USA
SOURCE: PCT Int. Appl., 99 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005076987	A2	20050825	WO 2005-US3791	20050204
WO 2005076987	A3	20060608		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SM				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005213472	A1	20050825	AU 2005-213472	20050204
CA 2554271	A1	20050825	CA 2005-2554271	20050204
US 20050249806	A1	20051110	US 2005-51260	20050204
EP 1718303	A2	20061108	EP 2005-722791	20050204
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
JP 2007522217	T	20070809	JP 2006-553174	20050204
MX 2006009036	A	20061019	MX 2006-9036	20060809

PRIORITY APPLN. INFO.: US 2004-543636P P 20040210
WO 2005-US3791 W 20050204

AB Pharmaceutical compns. comprising a proton pump inhibitor, one or more buffering agent and a nonsteroidal anti-inflammatory drug are described. Methods are described for treating gastric acid-related disorders and

treating inflammatory disorders, using pharmaceutical compns. comprising a proton pump inhibitor, a buffering agent, and a nonsteroidal anti-inflammatory drug. For example, a powder for suspension formulation contained omeprazole 20 mg, ibuprofen 400 mg, sodium bicarbonate 1895 mg, Xylitol 300 (sweetener) 2000 mg, sucrose (sweetener) 1750 mg, sucralose (sweetener) 125 mg, xanthan gum 17 mg, peach flavor 47 mg, and peppermint 26 mg.

IT 113712-98-4, Tenatoprazole 169590-42-5, Celecoxib
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination of proton pump inhibitor, buffering agent, and NSAID agent for treatment of gastric acid-related disorders and inflammation)

RN 113712-98-4 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine, 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]- (CA INDEX NAME)



RN 169590-42-5 CAPLUS
CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:492425 CAPLUS
DOCUMENT NUMBER: 143:13406
TITLE: Solid pharmaceutical formulations containing proton pump inhibitors and nonsteroidal antiinflammatory agents
INVENTOR(S): Takada, Shigeyuki; Koyama, Hiroyoshi; Hamaguchi, Tadashi
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 15 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2005145894	A	20050609	JP 2003-386548	20031117

PRIORITY APPLN. INFO.: JP 2003-386548 20031117
OTHER SOURCE(S): MARPAT 143:13406

AB The invention relates to a solid pharmaceutical formulation characterized by containing granules or tablet of a proton pump inhibitor (PPI), and granules of a nonsteroidal antiinflammatory agent (NSAID), wherein the addition of the PPIN in the formulation prevents gastrointestinal injury due to NSAID. For example, a capsule containing lansoprazole granules (lansoprazole 30 mg) and diclofenac sodium sustained-release granules (diclofenac sodium 100 mg) was formulated.

IT 113712-98-4, Tenatoprazole 169590-42-5, Celecoxib
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(solid pharmaceutical formulations containing proton pump inhibitors and nonsteroidal antiinflammatory agents)

RN 113712-98-4 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine, 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]- (CA INDEX NAME)



RN 169590-42-5 CAPLUS
CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)



L5 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:329905 CAPLUS
DOCUMENT NUMBER: 140:344896
TITLE: Pharmaceutical composition comprising tenatoprazole and an anti-inflammatory drug
INVENTOR(S): Schutze, Francois; Charbit, Suzy; Ficheux, Herve; Homerin, Michel; Taccoen, Alain; Inaba, Yoshio
PATENT ASSIGNEE(S): Negma Gild, Fr.; Mitsubishi Pharma Corporation
SOURCE: Fr. Demande, 15 pp.

CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2845917	A1	20040423	FR 2002-13115	20021021
FR 2845917	B1	20060707		
CA 2503211	A1	20040506	CA 2003-2503211	20031021
WO 2004037254	A1	20040506	WO 2003-FR3120	20031021
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003285424	A1	20040513	AU 2003-285424	20031021
EP 1553942	A1	20050720	EP 2003-778425	20031021
EP 1553942	B1	20060524		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003015455	A	20050823	BR 2003-15455	20031021
JP 2006506376	T	20060223	JP 2004-546112	20031021
CN 1744897	A	20060308	CN 2003-80107201	20031021
CN 100376245	C	20080326		
AT 326968	T	20060615	AT 2003-778425	20031021
PT 1553942	T	20061031	PT 2003-778425	20031021
ES 2265594	T3	20070216	ES 2003-778425	20031021
US 20060287284	A1	20061221	US 2006-532041	20060623

PRIORITY APPLN. INFO.:
FR 2002-13115 A 20021021
WO 2003-FR3120 W 20031021

AB A pharmaceutical composition comprises a combination of tenatoprazole and one or more NSAID and the inhibitors of cyclooxygenase-2 inhibitors for the treatment of the painful and inflammatory symptoms. A tablet contained tenatoprazole 20, diclofenac 100, and excipients q.s. 300 mg. Efficacy of the tablet in the treatment of patients with inflammation and pain is shown.

IT 113712-98-4, Tenatoprazole 169590-42-5, Celecoxib 335299-59-7 335299-60-0 884304-68-1 884304-69-2
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical composition comprising tenatoprazole and anti-inflammatory drugs)

RN 113712-98-4 CAPLUS

CN 3H-Imidazo[4,5-b]pyridine, 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]- (CA INDEX NAME)



RN 169590-42-5 CAPLUS
CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)



RN 335299-59-7 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine, 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-, sodium salt (1:1) (CA INDEX NAME)



RN 335299-60-0 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine, 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-, potassium salt (1:1) (CA INDEX NAME)



● K

RN 884304-68-1 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine, 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-, magnesium salt (2:1) (CA INDEX NAME)



●1/2 Mg

RN 884304-69-2 CAPLUS
CN 3H-Imidazo[4,5-b]pyridine, 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-, calcium salt (2:1) (CA INDEX NAME)



●1/2 Ca

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 8 OF 10 USPATFULL on STN
ACCESSION NUMBER: 2008:291166 USPATFULL
TITLE: SUBSTITUTED BENZIMIDAZOLES
INVENTOR(S): Gant, Thomas G., Carlsbad, CA, UNITED STATES
Sarshar, Sepehr, Cardiff by the Sea, CA, UNITED STATES
PATENT ASSIGNEE(S): AUSPEX PHARMACEUTICALS, INC., Vista, CA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080255200	A1	20081016
APPLICATION INFO.:	US 2008-100992	A1	20080410 (12)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2007-911266P	20070411 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: GLOBAL PATENT GROUP - APX, Ms. LaVern Hall, 10411 Clayton Road, Suite 304, ST. LOUIS, MO, 63131, US
NUMBER OF CLAIMS: 85
EXEMPLARY CLAIM: 1
LINE COUNT: 3639
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed herein are substituted benzimidazole-based proton pump modulators of Formula I, processes of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.

##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 113712-98-4, Tenatoprazole 169590-42-5, Celecoxib
(codrug; preparation of substituted benzimidazole-based proton pump modulators useful in treatment and prevention of proton pump-mediated disorders)
RN 113712-98-4 USPATFULL
CN 3H-Imidazo[4,5-b]pyridine, 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]- (CA INDEX NAME)



RN 169590-42-5 USPATFULL
CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)



L5 ANSWER 9 OF 10 USPATFULL on STN
ACCESSION NUMBER: 2006:334669 USPATFULL
TITLE: Pharmaceutical composition combining tenatoprazole and an anti-inflamatory agent

INVENTOR(S): Schutze, Francois, 4, rue Charles Baudelaire, Saint-Nom-La-Breteche, FRANCE F-78860
Charbit, Suzy, Creteil, FRANCE
Ficheux, Herve, Nogent-Sur-Marne, FRANCE
Homerin, Michel, Courcouronnes, FRANCE
Taccoen, Alain, Le Chesnay, FRANCE
Taccoen, Nathalie, Le Chesnay, FRANCE legal representative
Inaba, Yoshio, Chuo-Ku, Tokyo, JAPAN

PATENT ASSIGNEE(S): Negma Gild, Toussus Le Noble, FRANCE, F-78117 (non-U.S. corporation)
Mitsubishi Pharma Corporation, Tokyo, JAPAN, 103-8405 (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 20060287284	A1	20061221	
APPLICATION INFO.:	US 2003-532041	A1	20031021	(10)
	WO 2003-FR3120		20031021	
			20060623	PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	FR 2002-13115	20021021

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: BUCHANAN, INGERSOLL & ROONEY PC, POST OFFICE BOX 1404, ALEXANDRIA, VA, 22313-1404, US
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
LINE COUNT: 371
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a novel pharmaceutical combination. The inventive pharmaceutical composition comprises a combination of tenatoprazole and one or more anti-inflammatory agents preferably selected from non-steroid anti-inflammatory agents and cyclooxygenase-2 inhibitors. The invention is suitable for the treatment of painful and inflammatory manifestations.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 113712-98-4, Tenatoprazole 169590-42-5, Celecoxib 335299-59-7 335299-60-0 884304-68-1 884304-69-2
(pharmaceutical composition comprising tenatoprazole and anti-inflammatory drugs)
RN 113712-98-4 USPATFULL
CN 3H-Imidazo[4,5-b]pyridine, 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]- (CA INDEX NAME)



RN 169590-42-5 USPATFULL
CN Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)



RN 335299-59-7 USPATFULL
CN 3H-Imidazo[4,5-b]pyridine, 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-, sodium salt (1:1) (CA INDEX NAME)



● Na

RN 335299-60-0 USPATFULL
CN 3H-Imidazo[4,5-b]pyridine, 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-, potassium salt (1:1) (CA INDEX NAME)



● K

RN 884304-68-1 USPATFULL
CN 3H-Imidazo[4,5-b]pyridine, 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-, magnesium salt (2:1) (CA INDEX NAME)



●1/2 Mg

RN 884304-69-2 USPATFULL
CN 3H-Imidazo[4,5-b]pyridine, 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-, calcium salt (2:1) (CA INDEX NAME)



●1/2 Ca

L5 ANSWER 10 OF 10 USPATFULL on STN

ACCESSION NUMBER:	2005:286542 USPATFULL		
TITLE:	Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory drug		
INVENTOR(S):	Proehl, Gerald T., San Diego, CA, UNITED STATES Olmstead, Kay, San Diego, CA, UNITED STATES Hall, Warren, Del Mar, CA, UNITED STATES		
PATENT ASSIGNEE(S):	Santarus, Inc. (U.S. corporation)		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20050249806	A1	20051110
APPLICATION INFO.:	US 2005-51260	A1	20050204 (11)
	NUMBER		DATE
PRIORITY INFORMATION:	US 2004-543636P		20040210 (60)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	WILSON SONSINI GOODRICH & ROSATI, 650 PAGE MILL ROAD, PALO ALTO, CA, 94304-1050, US		
NUMBER OF CLAIMS:	38		
EXEMPLARY CLAIM:	1		
LINE COUNT:	4004		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Pharmaceutical compositions comprising a proton pump inhibitor, one or more buffering agent and a nonsteroidal anti-inflammatory drug are described. Methods are described for treating gastric acid related disorders and treating inflammatory disorders, using pharmaceutical compositions comprising a proton pump inhibitor, a buffering agent, and a nonsteroidal anti-inflammatory drug.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 113712-98-4, Tenatoprazole 169590-42-5, Celecoxib
        (combination of proton pump inhibitor, buffering agent, and NSAID agent
        for treatment of gastric acid-related disorders and inflammation)
RN   113712-98-4 USPATFULL
CN   3H-Imidazo[4,5-b]pyridine, 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-
       pyridinyl)methyl]sulfinyl]- (CA INDEX NAME)



RN   169590-42-5 USPATFULL
CN   Benzenesulfonamide, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-
       yl]- (CA INDEX NAME)



=> d his

     (FILE 'HOME' ENTERED AT 09:43:42 ON 18 FEB 2009)

     FILE 'REGISTRY' ENTERED AT 09:44:00 ON 18 FEB 2009
                E "TENATOPRAZOLE"/CN 25
L1   1 S E3
L2   6 S E3 OR E4 OR E5 OR E6 OR E7 OR E8
                E "CELECOXIB"/CN 25
L3   1 S E3
L4   6 S E3 OR E4 OR E5 OR E6 OR E7 OR E8

     FILE 'MEDLINE, CAPLUS, WPIDS, USPATFULL' ENTERED AT 09:46:28 ON 18 FEB
     2009
L5   10 S L2 AND L4

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	69.02	150.16

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-5.74	-5.74

STN INTERNATIONAL LOGOFF AT 09:48:03 ON 18 FEB 2009